Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road-Reference-Cited by-同舟云学术

Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

Published:2022-07-25 Issue:19 Volume:28 Page:4167-4170
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Adrianzen-Herrera Diego A.¹^ORCID,Shastri Aditi²^ORCID

Affiliation:

1. 1Division of Hematology and Oncology, Department of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.

2. 2Division of Hematologic Malignancies and Cellular Therapies, Department of Oncology, Albert Einstein College of Medicine, Bronx, New York.

Abstract

SummaryA sizable proportion of patients with acute myeloid leukemia (AML) fail to achieve remission. Hematopoietic stem cell transplantation (HSCT) is the only intervention with potential of long-term survival. A recent Acute Leukemia Working Party (ALWP)/European Society for Blood and Marrow Transplantation (EBMT) analysis reports substantial posttransplant survival gains for patients with active disease who received transplants. Decreased relapse was the largest contributor to survival, a cause for optimism in this challenging population.See related article by Nagler et al., p. 4258

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-1881/3182540/ccr-22-1881.pdf

Reference20 articles.

1. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis;Nagler;Clin Cancer Res,2022

2. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel;Dohner;Blood,2017

3. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure;Duval;J Clin Oncol,2010

4. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo;Todisco;Leukemia,2013

5. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT);Poiani;Am J Hematol,2021